<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01164345</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-7481-AN-CTIL</org_study_id>
    <nct_id>NCT01164345</nct_id>
  </id_info>
  <brief_title>Mozobil for Autologous Stem Cell Mobilization</brief_title>
  <official_title>Plerixafor (Plerixafor AMD 3100) + Recombinant Human G-CSF (rhG-CSF) for Autologous Peripheral Blood Stem Cell Transplantation (AutoSCT) in Hard to Mobilise Patients: a Phase IIB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF
      (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL)
      patients for autologous transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Mobilisation success rate</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mobilisation success rate is defined as the mobilisation of a PBSC graft containing &gt;2x106 CD34+ cells/kg in ≤ 4 apheresis sessions. We will evaluate the time from chemotherapy to stem cell collection,number of collections required to reach &gt;2x106 CD34+ cells/kg, number of CD34+ cells collected and percentage of patients reaching &gt;5x10 CD34+ cells/kg in ≤ 4 apheresis sessions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>engraftment after transplantation</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>speed of engraftment is determined by the time until recovery of blood counts after transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Stem Cell Mobilization</condition>
  <condition>Autologous Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>MOZOBIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with mozobil for autologous stem cell collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10  hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.</description>
    <arm_group_label>MOZOBIL</arm_group_label>
    <other_name>Mozobil and Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients eligible and planned for an autologous haematopoietic stem cell transplantation.

        1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

        1.2 WBC count ≥2.5x109/L.

        1.3 Absolute neutrophil count ≥1.5x109/L.

        1.4 Platelet count ≥100x109/L

        1.5 Adequate cardiac, renal, hepatic and pulmonary function sufficient to undergo
        apheresis and transplantation.

        1.6 Previously, heavily pretreated lymphoma patients or patients suspected to have a poor
        bone marrow stem cell reserve for at least one of the following:

          -  &gt;2 lines of chemotherapy.

          -  Previous radiotherapy involving bone marrow

          -  Prior therapy with specific stem cell toxic chemotherapeutic agents

          -  Platelets count pre-mobilisation, ≤150.103 x mm3

          -  Level of circulating CD34+ ≤ 20 cells/mcL prior to apheresis on the collection day

          -  Patients &gt; 60 years of age

        Exclusion Criteria:

        2.1 Lymphoma patients that did not fulfil the inclusion criteria.

        2.2 History of any acute or chronic leukemia (including myelodysplastic syndrome.

        2.3 Prior allogeneic or autologous transplantation.

        2.4 Inability to tolerate stem cell harvest.

        2.5 Peripheral venous access not possible.

        2.6 Pregnant or nursing women.

        2.7 Positive serology for hepatitis B or C.

        2.8 Acute infection (febrile, i.e. temperature &gt; 38C) within 24 hours prior to dosing or
        antibiotic therapy within 7 days prior to the first dose of GCSF.

        2.9 HIV positive.

        2.10 Left ventricular ejection fraction &lt; 50%.

        2.11 DLCO &lt; 50%.

        2.12 Splenectomised or splenic irradiation.

        2.13 Psychiatric, addictive, or any disorder/disease which compromises ability to give
        informed consent for participation in this study.

        2.14 Treatment with other investigational drugs within 4 weeks of enrolling in this
        protocol or currently enrolled in another investigational protocol during the mobilisation
        phase.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnon Nagler, MD</last_name>
    <phone>972 3 530 5830</phone>
    <email>a.nagler@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Avichai Shimoni, MD</last_name>
    <phone>972 3 530 5303</phone>
    <email>ashimoni@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Nagler, MD</last_name>
      <phone>972 3 530 5830</phone>
      <email>a.nagler@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Arnon Nagler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 23, 2011</lastchanged_date>
  <firstreceived_date>July 12, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Arnon Nagler, MD</name_title>
    <organization>Chaim Sheba Medical Center</organization>
  </responsible_party>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>stem cell mobilization</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
</clinical_study>
